TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12167135
Drug: Tizanidine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (mean dose 18 mg, titrated to maximum 24 mg over 4 weeks)
Study: 10210050
Drug: Tramadol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 0.5 mg x kg(‐1)
Study: 10210050
Drug: Tramadol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 0.25 mg x kg(‐1)
Study: 10210050
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.05 ml x kg(‐1)
Study: 8590121
Drug: Continuous cold
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous cold therapy (cold therapy pads placed over a thin dressing, maintained at 42 degrees F for the immediate postoperative period, used for an average of 3 days)
Study: 8590121
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (identical operative and postoperative procedure without continuous cold therapy)
Study: 2709943
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 therapy
Study: 2709943
Drug: No prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prostaglandin E1 therapy (Control)
Study: 27282117
Drug: Enhanced treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment-as-usual
Study: 31036412
Drug: Glucomannan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan (3 g/d for 12 weeks)
Study: 31036412
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 3 g/d for 12 weeks)
Study: 27489077
Drug: Guided Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-based cognitive behavioral therapy (ICBT) for 9 weeks
Study: 27489077
Drug: Guided Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-based cognitive behavioral therapy (ICBT)
Study: 23786339
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin (4 mU/min, increasing every 30 minutes to 64 mU/min)
Study: 23786339
Drug: Standard-dose oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose oxytocin (2 mU/min, increasing every 30 minutes to 32 mU/min)
Study: 23786339
Drug: Standard-dose oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose oxytocin
Study: 19914604
Drug: L-DOPA (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA (300 mg)
Study: 12727080
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg b.i.d. for 20 days
Study: 31072359
Drug: Pyriproxyfen (PPF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyriproxyfen (PPF) dissemination devices (0.2-0.3 g PPF in clay pots)
Study: 26885511
Drug: Toyra(®) virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toyra(®) virtual reality system combined with conventional therapy
Study: 21095620
Drug: G-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (10 μg/kg s.c. for 5 days)
Study: 8804929
Drug: Inhaled lysine-acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lysine-acetylsalicylate (L-ASA) 90 mg.mL-1
Study: 8804929
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo (glycine, 30 mg.mL-1)
Study: 622844
Drug: Ajmaline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ajmaline (50 mg)
Study: 6368960
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (CP) subcutaneous on day 14
Study: 6368960
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (CP) intravenous on day 14
Study: 6368960
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (CP) subcutaneous on day 1
Study: 6368960
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (CP) intravenous on day 1
Study: 6368960
Drug: VAC/FMC chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC/FMC chemotherapy
Study: 30698045
Drug: GP2017 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP2017 (40 mg subcutaneous injection)
Study: 29752620
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Body Image and Self-Care (CBT-BISC)
Study: 25689042
Drug: Malabsorption blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malabsorption blood test (MBT) with pancreatic enzyme administration
Study: 25689042
Drug: Malabsorption blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malabsorption blood test (MBT) without pancreatic enzyme administration
Study: 22483680
Drug: Nabiximols (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols (low dose: 1-4 sprays/day)
Study: 22483680
Drug: Nabiximols (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols (medium dose: 6-10 sprays/day)
Study: 22483680
Drug: Nabiximols (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols (high dose: 11-16 sprays/day)
Study: 11682411
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL mouth-to-mouth ventilation tidal volume
Study: 11682411
Drug: 1000 mL
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL mouth-to-mouth ventilation tidal volume
Study: 2566112
Drug: Acebutolol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 600 mg
Study: 2566112
Drug: Carteolol 20
Normalized name: carteolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol 20 mg
Study: 269633
Drug: No oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No oxytocin infusion (Control)
Study: 31488492
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zoledronic acid (ZA)
Study: 24144899
Drug: efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz (EFV) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)
Study: 21594217
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (2 g amoxicillin single preoperative dose)
Study: 21594217
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (single preoperative 2 g amoxicillin followed by 500 mg three times daily for 5 days)
Study: 21594217
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (postoperative amoxicillin with clavulanic acid 625 mg three times daily for 5 days)
Study: 16459722
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg once weekly (OW) interferon beta-1a
Study: 9241002
Drug: Moclobemide 900
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 900 mg daily
Study: 29105489
Drug: Short-term CHS
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term CHS + vitamin C (12 g/100 l drinking water)
Study: 20150450
Drug: Intensified dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified dosing of enteric‐coated mycophenolate sodium (EC‐MPS) - 2880 mg/d for days 0-14, 2160 mg/d for days 15-42, followed by 1440 mg/d
Study: 20150450
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of enteric‐coated mycophenolate sodium (EC‐MPS) - 1440 mg/d
Study: 20150450
Drug: Intensified dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified dosing of enteric‐coated mycophenolate sodium (EC‐MPS)
Study: 20150450
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of enteric‐coated mycophenolate sodium (EC‐MPS)
Study: 1683250
Drug: Abanoquil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abanoquil (0.5 micrograms kg‐1, intravenous bolus)
Study: 7228474
Drug: Elsinore pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elsinore pills (ephedrine and caffeine)
Study: 26510727
Drug: PanAd3-RSV and
Approvals — FDA: no, EMA: no, PMDA: no
Description: PanAd3-RSV and MVA-RSV vaccines (various combinations)
Study: 26510727
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of IM MVA-RSV
Study: 22204725
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus bevacizumab (7.5 mg/kg), given every 3 weeks for 5 or 6 cycles and continued for 12 additional cycles or until progression of disease.
Study: 22204725
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (carboplatin and paclitaxel), given every 3 weeks for 6 cycles.
Study: 22204725
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus bevacizumab (7.5 mg/kg).
Study: 22204725
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (carboplatin and paclitaxel).
Study: 17202550
Drug: Integrated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated group therapy
Study: 21689897
Drug: Group drug
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group drug counseling
Study: 335791
Drug: L-tryptophan (L-TP)
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan (L-TP) 6 g daily with unilateral ECT
Study: 335791
Drug: L-TP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-TP treatment
Study: 335791
Drug: L-TP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-TP treatment with ECT
Study: 26967236
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic blood pressure target of less than 120 mm Hg)
Study: 26967236
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systolic blood pressure target of less than 140 mm Hg)
Study: 21555684
Drug: Anastrozole plus
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole plus goserelin (3.6 mg subcutaneously every 28 days)
Study: 16822129
Drug: Grasping and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grasping and using an object (e.g., drinking from a cup)
Study: 8791035
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg 5-HTP
Study: 8791035
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg 5-HTP
Study: 8791035
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg 5-HTP
Study: 25607709
Drug: Sinecatechins 15%
Normalized name: SINECATECHINS 15% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinecatechins 15% ointment BID
Study: 23121257
Drug: Aspirin 150
Normalized name: aspirin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 150 mg/day
Study: 15717109
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with myasthenia gravis (MG)
Study: 11147733
Drug: Daily-disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily-disposable
Study: 9301443
Drug: GM-CSF, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF, 300 micrograms/day administered subcutaneously on days 3-6, 10-13, 17-20, and 24-27 during chemotherapy
Study: 9301443
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered during chemotherapy
Study: 8421111
Drug: 0.12% chlorhexidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine, 100 ppm fluoride mouthrinse, rinsed 2x per day for 1 min with 15 ml for 6 weeks
Study: 3950051
Drug: Trimoprostil 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimoprostil 0.25 mg
Study: 3950051
Drug: Trimoprostil 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimoprostil 0.75 mg
Study: 3089691
Drug: Trimoprostil 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimoprostil 1.5 mg
Study: 3089691
Drug: Trimoprostil 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimoprostil 3.0 mg
Study: 3950051
Drug: Trimoprostil (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimoprostil (0.75 mg to 3.0 mg)
Study: 22422589
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) using drug-eluting stents (DES) (n=556)
Study: 18672531
Drug: NVP 400
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP 400 mg per day
Study: 18672531
Drug: NVP 600
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP 600 mg per day
Study: 16306519
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (1000 mg per day, increased to 3000 mg per day)
Study: 12475577
Drug: Short-term low-dose
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term low-dose heparin plus bedrest
Study: 1503287
Drug: Cefamandole intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole intravenously every four hours, three times, starting from induction of anaesthesia (1.5 g for <60 kg, 2.5 g for 60-80 kg, 3 g for >80 kg)
Study: 1503287
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at the same times
Study: 6434168
Drug: 2% sodium
Normalized name: Dextrose 5% and 0.2% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% sodium cromoglycate ophthalmic solution
Study: 6434168
Drug: 4% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% sodium cromoglycate ophthalmic solution
Study: 27792720
Drug: simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin plus inulin (20 mg simvastatin, 7 g inulin)
Study: 27792720
Drug: simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin plus ezetimibe (20 mg simvastatin, 10 mg ezetimibe)
Study: 23046608
Drug: Trauma-Focused Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) (10-12 weeks)
Study: 17586424
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (2.4 g daily for 8 weeks)
Study: 17586424
Drug: Control (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (olive oil, 2.4 g daily for 8 weeks)
Study: 10023787
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg/d for 1 week, then tapered over 3 weeks)
Study: 2216227
Drug: Topical bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bupivacaine hydrochloride on both fallopian tubes
Study: 2216227
Drug: Topical bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bupivacaine hydrochloride on the right fallopian tube only
Study: 2216227
Drug: Topical bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bupivacaine hydrochloride on the left fallopian tube only
Study: 31194960
Drug: Biting activity
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biting activity of An. gambiae s.l. outdoors
Study: 31194960
Drug: Biting activity
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biting activity of An. funestus s.l. outdoors
Study: 31194960
Drug: Biting activity
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biting activity of An. funestus s.l. indoors
Study: 31194960
Drug: Biting activity
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biting activity of An. gambiae s.l. during wet season
Study: 31194960
Drug: Biting location
Normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biting location preference of An. gambiae s.l.
Study: 31194960
Drug: Biting location
Normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biting location preference of An. funestus s.l. during wet season
Study: 31194960
Drug: Biting location
Normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biting location preference of An. funestus s.l. during dry season
Study: 28785809
Drug: Mud-bath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud-bath therapy (MBT) group: daily treated with a combination of local mud-packs at 42 °C and baths in mineral water at 37 °C for 15 min, for 12 applications over a period of 2 weeks, in addition to standard therapy.
Study: 28785809
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: continued their conventional treatment alone.
Study: 25874654
Drug: Drug prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug prescriptions
Study: 24132057
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light + melatonin capsule
Study: 24132057
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light + placebo capsule
Study: 24132057
Drug: Dim light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim light (placebo) + melatonin capsule
Study: 24132057
Drug: Dim light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim light (placebo) + placebo capsule
Study: 24132057
Drug: Combined bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined bright light + melatonin treatment
Study: 19175712
Drug: Lafutidine 10
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafutidine 10 mg twice daily for 12 weeks plus gargling with azulene sulfonate sodium (ASS)
Study: 16394041
Drug: Water-based lubricant
Normalized name: Trojan H2O Closer Water-Based Lubricants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-based lubricant (0.5 mL contaminated specimen)
Study: 1759375
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with psychotherapy
Study: 1759375
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment without psychotherapy
Study: 6176753
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (Velban, Bleomycin, Cis-Platinum, Ifosfamid)
Study: 17413907
Drug: Remifentanil 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0 ng/ml
Study: 17413907
Drug: Remifentanil 2
Normalized name: remifentanil 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2 ng/ml
Study: 22289530
Drug: Remifentanil 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 4 ng/ml
Study: 10459691
Drug: Methylcobalamin (Met-12)
Normalized name: Met
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylcobalamin (Met-12) - large dosage
Study: 10459691
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - small dosage
Study: 7778622
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (0.5 mg, three doses 6 hours apart)
Study: 7778622
Drug: Estradiol cream
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol cream (4 mg, three doses 6 hours apart)
Study: 7778622
Drug: Oxytocin (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (at induction per protocol with an infusion pump)
Study: 24503408
Drug: 10 mg/mL
Normalized name: urea 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/mL posterior subtenon injection of nanoparticle carboplatin
Study: 9098274
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment after trabeculectomy
Study: 9098274
Drug: Nonsteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroid treatment after trabeculectomy
Study: 31788828
Drug: Combination thulium
Normalized name: thulium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination thulium laser and photodynamic therapy (TL-PDT)
Study: 30978265
Drug: Aprepitant therapy
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant therapy
Study: 28449280
Drug: ondansetron 150
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron 150 μg.kg‐1
Study: 28449280
Drug: droperidol 10
Normalized name: droperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 10 μg.kg‐1
Study: 24084214
Drug: Irbesartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (angiotensin receptor blocker)
Study: 24084214
Drug: Atenolol (beta-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta-adrenergic receptor blocker)
Study: 16292089
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose of omeprazole (20 mg; 60 mg/3 days)
Study: 16292089
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of omeprazole (80 mg bolus + 8 mg/h; 652 mg/3 days)
Study: 16292089
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose of omeprazole
Study: 16292089
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of omeprazole
Study: 12465390
Drug: HCFU 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCFU 300 mg/day orally from day 14 for a year, plus intravenous mitomycin C (MMC) 6 mg/m2 on day 0 and 7 after surgery.
Study: 12465390
Drug: Intravenous mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mitomycin C (MMC) 6 mg/m2 on day 0 and 7 after surgery.